Eli Lilly & Co. announced Wednesday that it will reduce prices for some of its older insulins and expand a cap on costs insured patients pay when they fill prescriptions, providing critical relief to people with diabetes who can face annual costs of more than $1,000 for insulin. The drugmaker said the cap on out-of-pocket costs will take effect immediately, though the high cost of insulin in the U.S. is still a major issue.
